ANDA 85769, held by Watson Laboratories. Brompheniramine Maleate.
As of Nov 21, 2026, ANDA 85769 (Brompheniramine Maleate), held by Watson Laboratories, was not approved, with 1 approved supplement and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Brompheniramine Maleate4MG · tablet;oral | Brompheniramine Maleate | Discontinued |
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 22, 1986 | Supplement 8Manufacturing | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters